Medtronic Dirección

Dirección controles de criterios 4/4

El CEO de Medtronic's es Geoff Martha , nombrado en Apr 2020, tiene una permanencia de 4.42 años. compensación anual total es $15.39M, compuesta por 8.8% salario y 91.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.004% de las acciones de la empresa, por valor de $4.51M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 9.3 años, respectivamente.

Información clave

Geoff Martha

Chief Executive Officer (CEO)

US$15.4m

Compensación total

Porcentaje del salario del CEO	8.8%
Permanencia del CEO	4yrs
Participación del CEO	0.004%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	9.3yrs

Actualizaciones recientes de la dirección

Recent updates

35% Undervalued? Medtronic's Future Looks Very Bright

Apr 12

Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now

Mar 27

Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth

Mar 11

Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69

Mar 11

Medtronic: Its Recent Beat Proves That It Continues To Be A Rock

Feb 25

Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts

Feb 22

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued

Oct 19

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Oct 04

Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%

Sep 27

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69

Sep 18

Medtronic: The Tide Is Turning

Aug 24

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69

Aug 21

Medtronic: Dark Clouds Are Clearing - Outperformance Ahead

Aug 14

Return Trends At Medtronic (NYSE:MDT) Aren't Appealing

Aug 11

Medtronic: Expanding Product Portfolio Without Affecting Dividend Growth

Jul 15

Are Medtronic plc (NYSE:MDT) Investors Paying Above The Intrinsic Value?

Jul 09

Is Medtronic (NYSE:MDT) A Risky Investment?

Jun 21

Medtronic: Weak Forecasts Spoiled Strong Results For The Reporting Quarter

Jun 21

Is Medtronic's Dividend In A Good Place?

Jun 14

Medtronic (NYSE:MDT) Is Increasing Its Dividend To $0.69

Jun 03

Medtronic: Solid Q4 Earnings, Don't Fret About Guidance

May 26

Investors Met With Slowing Returns on Capital At Medtronic (NYSE:MDT)

May 04

Does This Valuation Of Medtronic plc (NYSE:MDT) Imply Investors Are Overpaying?

Mar 10

Where Will Medtronic Stock Be In 4 Years?

Feb 17

Medtronic: A Trend Change May Be Underway Ahead Of Earnings

Feb 06

Medtronic recalls ~23K Mahurkar hemodialysis catheters

Jan 30

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Geoff Martha en comparación con los beneficios de Medtronic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jan 26 2024	n/a	n/a	US$4b
Oct 27 2023	n/a	n/a	US$4b
Jul 28 2023	n/a	n/a	US$4b
Apr 28 2023	US$15m	US$1m	US$4b
Jan 27 2023	n/a	n/a	US$4b
Oct 28 2022	n/a	n/a	US$4b
Jul 29 2022	n/a	n/a	US$5b
Apr 29 2022	n/a	n/a	US$5b
Jan 28 2022	n/a	n/a	US$5b
Oct 29 2021	n/a	n/a	US$5b
Jul 30 2021	n/a	n/a	US$4b
Apr 30 2021	US$18m	US$1m	US$4b
Jan 29 2021	n/a	n/a	US$3b
Oct 30 2020	n/a	n/a	US$4b
Jul 31 2020	n/a	n/a	US$4b
Apr 24 2020	US$6m	US$905k	US$5b
Jan 24 2020	n/a	n/a	US$5b
Oct 25 2019	n/a	n/a	US$5b
Jul 26 2019	n/a	n/a	US$4b
Apr 26 2019	US$4m	US$693k	US$5b

Compensación vs. Mercado: La compensación total ($USD15.39M) de Geoff está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.52M).

Compensación vs. Ingresos: La compensación de Geoff ha sido consistente con los resultados de la empresa en el último año.

CEO

Geoff Martha (53 yo)

4yrs

Permanencia

US$15,394,632

Compensación

Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Chairman at Medtron...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Geoffrey Martha	Chairman of the Board & CEO	4yrs	US$15.39m	0.0042% $ 4.5m
Karen Parkhill	Executive VP & CFO	7.8yrs	US$6.12m	0.0050% $ 5.4m
Sean Salmon	Executive VP & President of Cardiovascular Portfolio	no data	US$5.36m	0.0019% $ 2.0m
Robert J. ten Hoedt	Executive VP & President of Global Regions	9.3yrs	US$5.05m	0.0024% $ 2.6m
Mark Ploof	Senior Vice President of Global Operations and Business Services	7.5yrs	sin datos	sin datos
Jennifer Kirk	Senior VP	2.8yrs	sin datos	0.00099% $ 1.1m
Kenneth Washington	Senior VP and Chief Technology & Innovation Officer	less than a year	sin datos	sin datos
Laura Mauri	Senior VP and Chief Scientific	2yrs	sin datos	sin datos
Ryan Weispfenning	VP & Head of Investor Relations	8.8yrs	sin datos	sin datos
Ivan Fong	Executive VP	2.2yrs	US$11.72m	0.00082% $ 885.1k
Torod Neptune	Senior VP & Chief Communications Officer	3.3yrs	sin datos	sin datos
Matt Walter	Chief Human Resources Officer	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MDT se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Geoffrey Martha	Chairman of the Board & CEO	4.4yrs	US$15.39m	0.0042% $ 4.5m
Scott Donnelly	Independent Director	11.3yrs	US$365.01k	0.00099% $ 1.1m
Kendall Powell	Independent Director	17.3yrs	US$350.01k	0.0013% $ 1.4m
Randall Hogan	Independent Director	9.3yrs	US$385.01k	0.0031% $ 3.3m
Craig Arnold	Lead Independent Director	9.3yrs	US$410.01k	0.0026% $ 2.8m
Denise O'Leary	Independent Director	24.3yrs	US$375.01k	0.0028% $ 3.1m
Andrea Goldsmith	Independent Director	5.1yrs	US$370.01k	0.00033% $ 356.2k
Elizabeth Nabel	Independent Director	10.3yrs	US$370.01k	0.00088% $ 949.9k
Lidia Fonseca	Independent Director	1.8yrs	US$294.37k	sin datos
Kevin Lofton	Independent Director	3.6yrs	US$370.01k	0.00017% $ 183.5k
Gregory Lewis	Independent Director	less than a year	sin datos	sin datos

9.3yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de MDT se considera experimentada (9.3 años de antigüedad promedio).

Medtronic Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Insider notifies of intention to sell stock

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Recent updates

Now 21% undervalued after recent price drop

35% Undervalued? Medtronic's Future Looks Very Bright

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now

Upcoming dividend of US$0.69 per share

Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth

Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69

Third quarter dividend of US$0.69 announced

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Medtronic: Its Recent Beat Proves That It Continues To Be A Rock

Insider notifies of intention to sell stock

Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

A Look At The Fair Value Of Medtronic plc (NYSE:MDT)

Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?

Medtronic Stock's Rally Is Set To Continue

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Medtronic's (NYSE:MDT) Dividend Will Be $0.69

Upcoming dividend of US$0.69 per share at 3.5% yield

Medtronic: The GLP-1 Drug Headwinds Are Overblown

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

3.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes

Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings

Medtronic Faces Potential Decline Despite Financial Strength

Now 21% undervalued after recent price drop

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69

Upcoming dividend of US$0.69 per share at 3.4% yield

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic: The Tide Is Turning

Medtronic plc Raises Earnings Guidance for 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Medtronic: Dark Clouds Are Clearing - Outperformance Ahead

Return Trends At Medtronic (NYSE:MDT) Aren't Appealing

Medtronic: Expanding Product Portfolio Without Affecting Dividend Growth

Are Medtronic plc (NYSE:MDT) Investors Paying Above The Intrinsic Value?

Full year 2023 earnings: EPS misses analyst expectations

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Is Medtronic (NYSE:MDT) A Risky Investment?

Medtronic: Weak Forecasts Spoiled Strong Results For The Reporting Quarter

Upcoming dividend of US$0.69 per share at 3.1% yield

Is Medtronic's Dividend In A Good Place?

Medtronic (NYSE:MDT) Is Increasing Its Dividend To $0.69

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic: Solid Q4 Earnings, Don't Fret About Guidance

Full year 2023 earnings: EPS misses analyst expectations

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Investors Met With Slowing Returns on Capital At Medtronic (NYSE:MDT)

Upcoming dividend of US$0.68 per share at 3.5% yield

Does This Valuation Of Medtronic plc (NYSE:MDT) Imply Investors Are Overpaying?

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind